ReviewMolecular and cellular endocrinology2014
Non-feminizing estrogens: a novel neuroprotective therapy.
Review in Molecular and cellular endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Estradiol Protects against Noise-Induced Hearing Loss and Modulates Auditory Physiology in Female Mice.International journal of molecular sciences · 2021Article
- Metabolic depletion of synaptosomal enzymes linked with neurotoxicity and ovarian dysfunction by phenolic antioxidants ofMetabolism open · 2021Article
- The Role of Estradiol in Traumatic Brain Injury: Mechanism and Treatment Potential.International journal of molecular sciences · 2020Review
- 17β-Estradiol Regulates Glucose Metabolism and Insulin Secretion in Rat Islet β Cells Through GPER and Akt/mTOR/GLUT2 Pathway.Frontiers in endocrinology · 2019Article
- Adverse neuropsychiatric development following perinatal brain injury: from a preclinical perspective.Pediatric research · 2019Review
- Ovarian aging is associated with gray matter volume and disability in women with MS.Neurology · 2018Article
- Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury.Progress in neurobiology · 2017Review
- Association between low thyroid-stimulating hormone, posterior cortical atrophy and nitro-oxidative stress in elderly patients with cognitive dysfunction.Archives of medical science : AMS · 2017Article
- Neuroprotective effects of estrogen in CNS injuries: insights from animal models.Neuroscience and neuroeconomics · 2017Article
- 17β-estradiol (E2) in membranes: Orientation and dynamic properties.Biochimica et biophysica acta · 2016Article
- An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease.Alzheimer's research & therapy · 2016Article
- Non-Feminizing Estrogens Do Not Exhibit Antidepressant-like Activity.Journal of pharmaceutics and drug research · 2016Article
- Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration.Brain research bulletin · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
While the conflict between basic science evidence for estrogen neuroprotection and the lack of effectiveness in clinical trials is only now being resolved, it is clear that strategies for estrogen neuroprotection that avoid activation of ERs have the potential for clinical application. Herein we review the evidence from both in vitro and in vivo studies that describe high potency neuroprotection with non-feminizing estrogens. We have characterized many of the essential chemical features of non-feminizing estrogens that eliminate or reduce ER binding while maintaining or enhancing neuroprotection. Additionally, we provide evidence that these non-feminizing estrogens have efficacy in protecting the brain from AD neuropathology and traumatic brain injury. In conclusion, it appears that the non-feminizing estrogen strategy for neuroprotection is a viable option to achieve the beneficial neuroprotective effects of estrogens while eliminating the toxic off-target effects of chronic estrogen administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.